Longeveron Inc.

Ladies and gentlemen, good afternoon and welcome to the Love Chevron fourth quarter and full year 2023 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mike Moyer, Managing Director of LifeSky Advisors. Please go ahead.

Thank you, operator. Good afternoon, everyone, and welcome to Longevron's 2023 year-end results conference call. Today, we will discuss financial results from the year ended December 31st, 2023 and provide a business update. After the market closed today, We issued a press release with these results, which can be found under the investor section of the Longevorone website. I am joined on the call today by the following members of Longevorone's management team. Mr. Wael Hashad, Chief Executive Officer, Dr. Natalia Agafanova, Chief Medical Officer, and Lisa Locklear, Chief Financial Officer. Mr. Hashad will begin with a brief corporate update, then Dr. Agafanova will review Longevorone's progress in its clinical programs, and Ms. Locklear will review the financial results for 2023. Following the company's prepared remarks, we will open the call to questions from covering analysts. As a reminder, during this call, we will make forward-looking statements which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our quarterly reports on Form 10-Q and annual report on Form 10-K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information. Now I'd like to turn the call over to Mr. Wael Ashad, Chief Executive Officer of Longevity. Wael.

Thank you, Mike. Good afternoon, everyone. We are pleased speaking with you today. On this call, we briefly recap of the major highlights for our year in 2023 and outline strategic priorities for 2024. then we will be happy to answer any questions you have. 2023 was a productive year for Longevron. During this year, that's 2023, we made significant progress advancing our lead asset, Lomacil-B, to important milestones. Presenting long-term survival data from our LPAS-1 clinical trial in hypoplastic left heart syndrome, at the American Heart Association annual meeting in Philadelphia and announcing clinically meaningful results from our Phase 2A ClearMind trial in Alzheimer's disease. We also took steps to strengthen our balance sheet, securing $6.4 million of gross proceeds from equity financing during the fourth quarter. For 2024, our strategic priorities are focused on our lead program in hypoplastic left heart syndrome, or HLHS, with the goal of completing enrollment in our ALPIS II Phase II clinical trial this year. ALPIS II has exceeded its 50% enrollment threshold, and we are working with the clinical investigators to expedite enrollment HLHS is our top priority program, and we believe our most important value driver in the near term. Accordingly, we made the strategic decision to discontinue our Phase II clinical program in aging-related frailty in Japan in order to focus on our available resources on HLHS and APHIS II enrollment. We are also exploring opportunities to advance our Alzheimer's disease program through potential partnership or other sources of funding. These steps will allow us to focus our available resources on completing enrollment in our ELPIS II study in 2024. The data that we have generated in HLHS and Alzheimer's disease all support broader potential for Lomacil-B as a regenerative medical therapy for range of unmet medical needs. Though we remain confident in the broader therapeutic potential of this asset, we believe that narrowing our focus in the near term on HLHS is the best interest of the patients, investors, and our shareholders. With that, I will turn the call to Dr. Axanova to provide you a review of the recent data on our clinical program so far. Natalia?